DPP7 and type 2 diabetes mellitus: In response to the addition of a DPP2/4 inhibitor SphK1b expression increased significantly, but not SphK1a [33], DPP4 is currently used as a drug to manage type II diabetes mellitus [62, 63] and is also associated with inflammatory control [62].